dc.date.accessioned2020-09-16T17:26:30Z
dc.date.accessioned2022-09-23T18:32:37Z
dc.date.available2020-09-16T17:26:30Z
dc.date.available2022-09-23T18:32:37Z
dc.date.created2020-09-16T17:26:30Z
dc.identifier2405-8440
dc.identifierhttps://doi.org/10.1016/j.heliyon.2020.e04900
dc.identifierhttp://hdl.handle.net/20.500.12010/13334
dc.identifierhttps://doi.org/10.1016/j.heliyon.2020.e04900
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3502856
dc.description.abstractThe COVID-19 outbreak emerged in December 2019 and has rapidly become a global pandemic. A great deal of effort has been made to find effective drugs against this disease. Chloroquine (CQ) and hydroxychloroquine (HCQ) were widely adopted in treating COVID-19, but the results were contradictive. CQ/HCQ have been used to prevent and treat malaria and are efficacious anti-inflammatory agents in rheumatoid arthritis and systemic lupus erythematosus. These drugs have potential broad-spectrum antiviral properties, but the underlying mechanisms are speculative. In this review, we re-evaluated the treatment outcomes and current hypothesis for the working mechanisms of CQ/HCQ as COVID-19 therapy with a special focus on disruption of Ca2þ signaling. In so doing, we attempt to show how the different hypotheses for CQ/HCQ action on coronavirus may interact and reinforce each other. The potential toxicity is also noted due to its action on Ca2þ and hyperpolarization-activated cyclic nucleotide-gated channels in cardiac myocytes and neuronal cells. We propose that intracellular calcium homeostasis is an alternative mechanism for CQ/HCQ pharmacology, which should be considered when evaluating the risks and benefits of therapy in these patients and other perspective applications.
dc.languageeng
dc.publisherHeliyon
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto Completo)
dc.sourcereponame:Expeditio Repositorio Institucional UJTL
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozano
dc.subjectChloroquine
dc.subjectHydroxychloroquine
dc.subjectCalcium
dc.subjectHCN
dc.subjectSARS-CoV-2
dc.subjectCardiology
dc.subjectPathology
dc.subjectInfectious disease
dc.subjectNeurology
dc.subjectPharmacology
dc.subjectImmunology
dc.subjectClinical toxicology
dc.subjectToxicology
dc.subjectEye-ear-nose-throat
dc.subjectInternal medicine
dc.titleChloroquine to fight COVID-19: A consideration of mechanisms and adverse effects?


Este ítem pertenece a la siguiente institución